AVCNEarnings•globenewswire•
Avicanna Reports Q2 2025
Sentiment:Negative (15)
Summary
TORONTO, Aug. 14, 2025 (GLOBE NEWSWIRE) -- Avicanna Inc. (“Avicanna” or “Company”) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN) a biopharmaceutical company focused on the development, manufacturing, and commercialization of plant-derived cannabinoid-based products is pleased to announce and report the results of Q2 2025.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on August 14, 2025 by globenewswire